Shares are Needed to execute $ENTB game plan.
10 Acquisitions in 16 months
Estimated revenue of 21 million
From PR's read below...
-------------------------------------------
A Spokesperson for the Company noted the National Canine Cancer Foundation says one in three dogs will be impacted by cancer. This staggering statistic shows not only the need for a cost effective treatment but also a treatment that is well tolerated. The potential revenue generated per patient is approximately $3,000 according to industry statistics. Management indicates that each veterinary hospital Entest will seek to acquire over the next two years will have a preexisting patient flow of at least 700 cancer patients per year. Once the first 10 veterinary hospitals have been acquired, Entest could possibly see 7,000 treatable canine patients per year at $3,000 per patient. This meaning, should Entest be successful in meeting its veterinary hospital acquisition target numbers [10 facilities], the company could potentially command revenues reflecting as much as $21 million per annum; treating dogs with cancer.
"Our primary goal is to continue growing the number of Veterinary Hospitals we own," stated Dr. David Koos, Chairman and CEO of Entest BioMedical. "In pursuing this segment of our business model, we will be able to continue growing our asset base, increase our current revenue stream and establish an initial distribution channel for our products and therapies; the first of these products being Entest's ImenVax immune-therapeutic canine cancer vaccine currently under development. Having a qualified Director of Corporate Affairs whose duties will consist primarily of identifying hospitals for acquisition and who possesses the skills required to substantially assist us in negotiating favorable purchase terms will be valuable in assisting the Company in achieving its goal of acquiring up to 10 additional veterinary clinics within the next 16 months." Entest currently owns and operates the McDonald Animal Hospital of Santa Barbara, CA which the company purchased in 2011. This facility serves as both a revenue source for Entest as well as a research facility for the biomedical company.
Market Data 
Markets 
AI
